This document describes the basis and regulatory requirements for the use of minimal residue disease as an intermediate endpoint to predict clinical benefit in trials in chronic lymphocytic leukaemia.
Keywords: Minimal residual disease (MRD), chronic lymphocytic leukaemia (CLL)